US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Telomir Pharmaceuticals, Inc. - Common Stock
(NQ:
TELO
)
1.200
-0.010 (-0.83%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telomir Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
January 28, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Findings for Age-Reversal Therapy
January 07, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
January 07, 2025
Via
ACCESSWIRE
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
December 23, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
August 20, 2024
Via
ACCESSWIRE
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
December 23, 2024
Via
ACCESSWIRE
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
↗
December 23, 2024
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.
Via
Benzinga
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
December 17, 2024
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Via
News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
December 12, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
December 12, 2024
Via
ACCESSWIRE
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
↗
December 03, 2024
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.
Via
Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
December 03, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
December 03, 2024
Via
ACCESSWIRE
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
November 22, 2024
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Via
News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
November 21, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
November 21, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
September 27, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
September 26, 2024
Via
ACCESSWIRE
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
September 05, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Via
News Direct
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
September 04, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
September 04, 2024
Via
ACCESSWIRE
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
August 19, 2024
Via
Benzinga
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
↗
August 13, 2024
Telomir Pharmaceuticals just reported results for the second quarter of 2024.
Via
InvestorPlace
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
May 31, 2024
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
Via
News Direct
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
↗
May 13, 2024
Telomir Pharmaceuticals just reported results for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
April 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
April 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 12, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
